|Bid||71.12 x 1000|
|Ask||71.74 x 44000|
|Day's Range||81.77 - 83.32|
|52 Week Range||66.72 - 92.97|
|PE Ratio (TTM)||11.48|
|Dividend & Yield||3.30 (3.50%)|
|1y Target Est||N/A|
AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).
Gaithersburg biotech Emergent BioSolutions is acquiring French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million. The company will pay $97.5 million up front to Sanofi and an additional $27.5 million in near-term regulatory and manufacturing milestone payments. Emergent will add the only smallpox vaccine licensed by the Food and Drug Administration to its existing portfolio of medical countermeasures to bioterrorism threats.
Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.